Wednesday - June 17, 2026
FDA Center for Drug Evaluation & Research Issues Warning Letter to HydraMed
June 17, 2026
WASHINGTON, June 17 -- The U.S. Department of Health and Human Services Food and Drug Administration issued the following warning letter to HydraMed IV LLC dba HydraMed from its Center for Drug Evaluation and Research:

* * *

Recipient: HydraMed IV LLC dba HydraMed, 4800 Dahlia St, Denver, CO 80216, United States, hello@hydramed.com

Issuing Office: Center for Drug Evaluation and Research (CDER), United States

WARNING LETTER

Referenc . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products